65,437 trials
Non-Infectious Uveitis
Primary: The Utilization of the Mk II Inserter From the Day of Treatment Through 7 Days Following Treatment. — 10; 3; 3; 2 Eyes
Walking Aided by a Leg Brace in Stroke Subjects
Primary: Self-selected Walking Velocity — 0.71; 0.74 m/s
Canthal Lines
Primary: Number of Responders on the Severity of Lateral Canthal Lines "at Maximum Smile". — 119; 6 Participants
Healthy
Primary: Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve From Time Zero to 8 Hours (AUC[0-8 Hours]) — 2440; 2430 picomole*hour/liter (pmol*h/L)
Interstitial Lung Disease
Primary: Lung Motion as Assessed by CT — 4.07; 5.56; 1.82; 2.46 Liters
Obesity
Primary: Caloric Intake — 531; 465; 444; 494 calories
Aortic Valve Stenosis
Primary: Improvement of the AVA and NYHA Functional Classification — 38.2; 45.8 % of participants
Healthy
Primary: Area Under the Lamotrigine Concentration vs. Time Curve From Sample Time Point 0 Hour to Sample Time Point 144 Hour. — 119966.6; 121969.5 h*ng/mL
Myalgic Encephalomyelitis · Chronic Fatigue Syndrome
Primary: Total Daily Symptom Score (TDSS) — 29.5; 28.7; 29.2; 31.3 units on a scale — p=0.011
Diabetes Mellitus, Type 1
Primary: Pharmacokinetics: Insulin Lispro Area Under the Concentration Versus Time Curve (AUC) for Each Treatment Arm — 1430; 1400; 1210; 1170 picomole * hour per Liter (pmol*h/L)
Cervical Disc Disease
Primary: Change in Number of Total Collisions (TC) — 2 collisions/crashes
Diabetes Mellitus, Type 1
Primary: Pharmacokinetics (PK): Insulin Lispro or Insulin Aspart Area Under the Concentration Curve From Zero to Seven Hours (AUC 0-7h) Following Administration of Each Study Arm…
Autism Spectrum Disorder
Primary: Longitudinal Pattern of ASD Screening in PCP Charts — 61; 64; 66; 64 percentage of children screened
Diabetes Mellitus, Type 2
Primary: Pharmacokinetics: Insulin Lispro Area Under the Concentration Versus Time Curve (AUC) Following LY900014 Administration — 1760; 1800; 2770; 1750 picomole * hour/Liter…
Herpes Zoster
Primary: Number of Subjects by Frailty Status, at Baseline — 11518; 12290; 3037; 131 Participants